Exciting News from Pharmidex!
March 21, 2025
We’re pleased to announce that
Janette Dalay Robertson, our Business Development Manager, and
Ian Knowles, our Head of Respiratory, will be attending the 2nd SMR Molecular Glues Meeting on Friday, 21st March 2025 at GSK, Stevenage.
This event is a fantastic opportunity to engage with fellow scientists, innovators, and industry leaders in the field of molecular glues.
Janette and Ian are eager to connect, share insights, and explore new collaborations to advance drug discovery and development.
If you’re attending, don’t hesitate to reach out – they would love to meet and discuss how
Pharmidex can support your research and development goals!
🔗 More about the event:
https://lnkd.in/d6yiTkUi
#Pharmidex #DrugDiscovery #MolecularGlues #Collaboration #Biotech #SMR2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
